October 17, 2017
Sponsored by
Cofactor Genomics

Profiling the Tumor Immune Microenvironment During Neoadjuvant Therapy for Soft-Tissue Sarcomas

GenomeWebinar

Join or Log in for Access

This content is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

This webinar discusses the benefits of genomically profiling the immune microenvironment of soft tissue sarcomas during neoadjuvant therapy.

Sarcomas are a group of more than 70 cancers of mesenchymal origin that together comprise approximately 1 percent of all cancers. On initial presentation, these tumors are often localized and curable. Surgery is the mainstay of therapy, but radiation and sometimes chemotherapy can also play an important role.

Sponsored by

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.

Oct
02
Sponsored by
Roche

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.  

Oct
04
Sponsored by
Agilent

This webinar will discuss the use of new software tools to support the diagnosis of CTFR-related disorders using next-generation sequencing.

Oct
10
Sponsored by
Philips Genomics

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.

Oct
11
Sponsored by
ArcherDX

This webinar will discuss a validation study for a next-generation sequencing (NGS) assay for hematological malignancies (e.g., acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms).